The Role of New Posaconazole Formulations in the Treatment of <em>Candida albicans</em> Infections:Data from an <em>in Vitro</em> Pharmacokinetic-Pharmacodynamic Model
Background Posaconazole is more in vitro active against Candida albicans than fluconazole and approved for the treatment of oropharyngeal candidiasis but not invasive candidiasis (IC). We explored the efficacy of posaconazole against C. albicans in an in vitro pharmacokinetic-pharmacodynamic (PK-PD) model of IC and determined the probability of pharmacodynamic target attainment for the oral solution (o.s.) and i.v./tablet formulations.Methods Three clinical C. albicans isolates (posaconazole…